Introduction
============

Cholangiocarcinoma (CCA), as a kind of malignancy from the bile duct epithelium,[@b1-ott-11-8211] was first described by Durand-Fardel in 1840. Regarding incidence, CCA is the second among all the primary hepatocellular carcinoma (HCC), taking up 3% of all the gastrointestinal neoplasms[@b2-ott-11-8211],[@b3-ott-11-8211] and 10%--25% of all the malignant HCCs. Besides, the CCA incidence has been growing recently. And there exist some differences about the epidemiological features between intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC). More specifically, there has been an enhanced ICC incidence, whereas there has been a reduced incidence of ECC in related nations, for instance, the USA and the UK.[@b4-ott-11-8211] The age-adjusted incidence ratio of ICC in the USA has increased by 165% in the past 20 years while the ratio of ECC has reduced by 14%.[@b5-ott-11-8211] Furthermore, the patients suffering from CCA have an especially poor prognosis. The related survival rates of generally 1, 3, and 5 years have been shown to be 25.0%, 9.7%, and 6.8%, respectively, almost without any changes recently.[@b6-ott-11-8211] Nonetheless, the causes of CCA are still not clear. Recently, some research studies have shown that liver diseases, like fatty liver disease and hepatitis B infection, are related to the development of CCA.[@b7-ott-11-8211],[@b8-ott-11-8211] In a similar way, the progression or development of CCA may be affected by alcoholic liver disease (ALD). Nonetheless, almost no information can be provided about the relationship between the development of CCA and ALD. As the main cause of mortality and morbidity in the world, ALD is the most common etiology of liver disease.[@b9-ott-11-8211] In fact, the ALD burden is the highest among developed nations, where it may occupy around 9.2% of all the years of life adjusted by disability.[@b10-ott-11-8211] Thus, both meta-analysis and systematic review were conducted in this study by enrolling related studies to gain a more thorough comprehension of the correlation of cirrhosis with the risk of CCA.

Methods
=======

The current study was conducted conforming to the PRISMA Statement[@b11-ott-11-8211] and the MOOSE guidelines.[@b12-ott-11-8211]

Sources of data and strategy of search
--------------------------------------

Databases such as Web of Science, EMBASE, and PubMed were searched for related research studies published with the usage of the following keywords: ("chronic liver disease" or "alcoholic liver disease" or "ALD" or "alcoholic fatty liver" or "chronic liver disease" or "steatosis" or "cirrhosis" or "fibrosis") and ("cholangiocarcinoma" or "biliary tract neoplasms" or "biliary tract cancer" or "bile duct cancer"). The publication date and language were not limited.

Inclusion criteria
------------------

Eligible research studies were included if they met the following criteria: study design (case--control or cohort); ALD as the factor of exposure; CCA or bile duct cancer or biliary tract cancer as the outcomes; the values of risk ratio (RR)/accessible OR with sufficient data or 95% CIs for calculation. The one with a bigger population was chosen in the case of the same data as reported by two research studies.

Data extraction and quality evaluation
--------------------------------------

Data extraction was conducted independently in the included studies, by WX and ZY, following the standard protocol. The following information was extracted from each paper: nation, publication year, name of the first author, design of study (case--control or cohort), number of subjects, confounding variables, follow-up duration, the values of OR/RR with 95% CIs, and the sources of controls.

Newcastle-Ottawa scale (NOS)[@b13-ott-11-8211] evaluated the quality of the study and the categories of the quality conformed to the scores of each study. The maximum score was 9 points. Specifically, the NOS scores of 7--9, 4--6, and \<4 showed high-, medium-, and low-quality studies, respectively.[@b14-ott-11-8211] The consensus dealt with all the discrepancies.

Statistical analysis
--------------------

The correlation of cirrhosis with the risk of CCA could be determined with the usage of the random-effects model proposed by DerSimonian and Laird.[@b15-ott-11-8211] Besides, the values of OR and 95% CIs were used to evaluate the correlation of ALD with the risk of CCA.

Heterogeneity between research studies was studied by the statistic of I[@b2-ott-11-8211], in which high, medium, and low heterogeneity meant 75%, 50%, and 25%, respectively.[@b16-ott-11-8211] In the case of *P*-value \<0.1, definite heterogeneity was taken into consideration. Meta-regression was used to study the exact heterogeneity degree of the research results with the year of publication (before 2010 vs 2010 and thereafter), number of cases (500 vs 500), geographical region (eastern vs western), and confounders adjusted for (cholangitis, hepatitis infection, and gallstones).

The analysis of subgroup was carried out based on the tumor subtype, geographic regions, and whether cholangitis, gallstones, and hepatitis infection were adjusted. Sensitivity analysis was carried out to evaluate the study effect on the concluded estimation by excluding one research in one turn sequentially. Sensitivity analyses were conducted by changing the pooling model (fixed-effects model or random-effects model).[@b17-ott-11-8211] Funnel plots and Begg's[@b18-ott-11-8211] and Egger's[@b19-ott-11-8211] tests were employed to assess the publication bias, where a *P*-value \<0.05 or funnel plot asymmetry was indicative of the bias.[@b20-ott-11-8211]

STATA version 12.0 (Stata) was applied in the statistical analysis
------------------------------------------------------------------

Results
=======

Selection and features of the research
--------------------------------------

[Figure 1](#f1-ott-11-8211){ref-type="fig"} shows the process of selection. About 9,275 papers were obtained via the initial search, where 3,027 were duplicates. According to the abstract and title, an extra 6,159 research studies were excluded. Fourteen research studies were eliminated for failure in meeting the inclusion criteria after thorough measurement of the full texts: insufficient statistics were identified in seven studies; four studies did not provide OR, or RR for CCA; and no access of OR, or RR for CCA or inadequate data for calculation of these variables in three studies. Thereby, seven observed studies were finally enrolled in this meta-analysis.[@b21-ott-11-8211]--[@b27-ott-11-8211]

[Table 1](#t1-ott-11-8211){ref-type="table"} shows the major features of the research studies in the meta-analysis.[@b21-ott-11-8211]--[@b27-ott-11-8211] The research studies were carried out in the following nations: one in China, Taiwan, and Korea, respectively, and four in the USA. The design of case--control was included in all the research studies. A total of 413,483 healthy controls and 8,962 subjects were chosen to investigate the role of ALD in the risk of CCA in the meta-analysis from 1978 to 2013. As presented in [Table 2](#t2-ott-11-8211){ref-type="table"}, the NOS scores of all the chosen studies ranged from 5 to 9; two of them had medium quality and five had high quality.

General results
---------------

Seven research studies that were case--control were integrated to examine the relation of ALD with the risk of CCA. As a result, it was found that the patients suffering from ALD had an enhanced related CCA risk in five studies. On the other hand, there was no important relation of ALD with the risk of CCA in only two studies. The pooled analysis showed a close relationship between CCA and ALD. To be more specific, as presented in [Figure 2](#f2-ott-11-8211){ref-type="fig"}, the risk of CCA was greatly enhanced by ALD (95% CI: 1.96--5.07; OR =3.92), with studies being significantly heterogeneous (I[@b2-ott-11-8211]=70.2%; *P*=0.003) ([Figure 2](#f2-ott-11-8211){ref-type="fig"}).

Analyses of sensitivity and subgroup
------------------------------------

[Table 3](#t3-ott-11-8211){ref-type="table"} shows the results of the sensitivity and subgroup analyses. As presented in [Table 3](#t3-ott-11-8211){ref-type="table"}, patients suffering from ALD in western nations were more intended to be burdened with CCA than the patients from the East (western nations: 95% CI: 3.34--6.96, OR =5.15; eastern nations: 95% CI: 0.38--3.91, OR =2.14) ([Table 3](#t3-ott-11-8211){ref-type="table"}) in the analysis of stratification by geographic region. In addition, as shown in [Table 3](#t3-ott-11-8211){ref-type="table"}, in the individual analysis of ECC and ICC, the results suggested that ALD had a positive effect on the risk of ICC and neutral effect on the risk of ECC (ICC: 95% CI: 3.06--5.92, OR =4.49; ECC: 95% CI: 0.90--3.35, OR =2.12). According to the sensitivity analysis, as shown in [Table 3](#t3-ott-11-8211){ref-type="table"}, the general results of the relationship between CCA and ALD were steady in transforming the pooling model (the random-effects model: 95% CI: 1.96--5.07; OR =3.92; the fixed-effects model: 95% CI: 2.31--3.44, OR =2.87). As shown in [Figure 3](#f3-ott-11-8211){ref-type="fig"}, the estimation of the pooled risk remained intact by any research in the sequential omission of study one by one to evaluate the stability of results. In addition, the analyses of meta-regression were conducted to study the possible heterogeneous origin. Thus, none of the below could be considered as the heterogeneity source, such as the number of cases (*P*=0.671), the year of publication (*P*=0.804), geographical regions (*P*=0.712), study quality (*P*=0.573), gallstones (*P*=0.448), cholangitis (*P*=0.819), and confounders adjusted for smoking status (*P*=0.740).

Bias of publication
-------------------

No substantial asymmetry was shown in the funnel plot. Neither Egger's test (*P*=0.741) nor Begg's test (*P*=0.605) showed any significant bias of publication (*P*\>0.05) ([Figure 4](#f4-ott-11-8211){ref-type="fig"}).

Discussion
==========

ALD refers to an identified risk factor of HCC.[@b28-ott-11-8211] Nonetheless, the role of ALD in CCA development as well as the relationship between CCA and ALD was comprehended poorly. Thus, it was shown that ALD was greatly related to CCA, which could greatly enhance the risk of CCA, especially in ICC.

It was shown in the current research that ALD was related to an enhanced risk of CCA. Nonetheless, the accurate cause of CCA was still not clear. First, alcohol could dispose people to CCA development via two mechanisms, including acetaldehyde and cytochrome P450 2E1 (CYP2E1). The induction of CYP2E1, metabolizing ethanol to acetaldehyde, could enhance the reactive production of oxygen species, the damage of DNA, and peroxidation of lipid. Acetaldehyde was generated by the ethanol metabolism and catalyzed by bacterial antidiuretic hormone and mucosal.[@b29-ott-11-8211] Acetaldehyde has been presented to have direct carcinogenic and mutagenic effects in in vivo and in vitro research studies.[@b30-ott-11-8211] Second, cholangiocarcinogenesis might be promoted by the consumption of alcohol via chronic inflammation that led to enhanced oxidative stress.[@b31-ott-11-8211]

Strengths
=========

There were some advantages in this research. First, this is the most comprehensive research that enrolled a large sample size (8,962 CCA patients in four nations) to investigate the possible role of ALD on the risk of CCA. The findings might offer valid information for the researchers of CCA and might be helpful to clinicians with the goal of establishing methods to prevent CCA development. In the second place, the analyses of sensitivity and subgroup were carried out to point out the factors that affected the risk of CCA. In addition, the comprehensive searches of Web of Science, PubMed, and EMBASE were carried out to extract the studies to investigate the factors that influenced the risk of CCA, which further proved the findings. Last but not least, the quality of the studies, such as the bias in the results, was evaluated in the meta-analysis. The random- and fixed-effects models were used to conclude the ALD effects on the CCA risk, and the results from the two model types were compared accordingly.

Limitations
===========

Nonetheless, there were certain restrictions in the research. First, all the research studies enrolled were case--control design, thus resulting in the recall generation and the biases of selection. In addition, the diagnostic bias might influence the results of the current research. ALD patients tended to have more frequent physical examination, which may lead to more diagnoses than controls. Second, the data about the antiviral treatment in the patients infected with HCV and HBV were unavailable, which may influence the risk of CCA development. Third, confounders might affect the relation between the risk of CCA and ALD. This study did not adjust the confounders, like particular dietary factors or cholangitis even though the adjustments for some con-founders that might have influenced the outcomes were conducted. Fourth, a meta-analysis on the effects of different types of ALD was not performed due to the limited number of included studies in the analysis. Moreover, many of the studies included in the meta-analysis did not indicate the type of ALD in the article. It may be considered another potential limitation of this study. Among the seven studies included, three studies reported results on cirrhosis,[@b3-ott-11-8211]--[@b5-ott-11-8211] with two studies showing a significantly increased the risk of CCA.[@b3-ott-11-8211],[@b4-ott-11-8211] And previous studies indicated that alcohol use was the major risk factor for ICC,[@b6-ott-11-8211] but not ECC.[@b7-ott-11-8211] In the meta-analysis, the results obtained by Lee et al suggested that alcohol did not obviously change the risk of CCA.[@b21-ott-11-8211] Last but not least, the number of studies on CCA was very less. Thereby, the assessment of heterogeneity and the pooled effects might be imprecise, and the researchers' publication bias could not be sufficiently evaluated. To solve the problem, some analyses of subgroup and sensitivity were conducted even though the source of heterogeneity was not always ascertained.

Conclusion
==========

It was demonstrated that the risk of CCA was enhanced by 3.92-fold by ALD. Furthermore, patients suffering from ALD tended to further develop ICC, instead of ECC. And more basic and prospective studies were carried out to further confirm the relation of ALD with the risk of CCA and to study the potential mechanisms.
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![The process of selecting studies for the meta-analysis.\
**Abbreviations:** ALD, alcoholic liver disease; CCA, cholangiocarcinoma; RR, risk ratio.](ott-11-8211Fig1){#f1-ott-11-8211}

![Forest plot showing the relationship between alcoholic liver disease and the risk of cholangiocarcinoma.\
**Notes:** Points represent the risk estimates for each individual study. Horizontal lines represent 95% CIs, and diamonds represent the summary risk estimates with 95% CIs. Weights are from random-effects analysis.\
**Abbreviation:** ES, effect size.](ott-11-8211Fig2){#f2-ott-11-8211}
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![Funnel plot of studies included in the meta-analysis of the relationship between alcoholic liver disease and the risk of cholangiocarcinoma.\
**Abbreviation:** SE, standard error.](ott-11-8211Fig4){#f4-ott-11-8211}

###### 

The main characteristics of the included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study/year of publication              Country   No. of case/control   Follow-up duration   Sources of controls   Subtype of cancer   Subtype of study   Adjusted factors                                                                                                                                                                                                                                                                                                   Adjusted OR (95% CI)
  -------------------------------------- --------- --------------------- -------------------- --------------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------
  Shaib et al, 2005[@b27-ott-11-8211]    USA       625/90,384            1993--1999           Hospital              ICC                 Case--control      Age, gender, race, geographic location, and Medicare/Medicaid dual enrollment                                                                                                                                                                                                                                      7.4 (4.3--12.8)

  Welzel et al, 2007[@b26-ott-11-8211]   USA       764/3,056             1978--1991           Population            ICC                 Case--control      Nonspecific cirrhosis, cholangitis, choledocholithiasis, inflammatory bowel disease, diabetes, obesity                                                                                                                                                                                                             10.67 (2.83--40.21)

  Welzel et al, 2007[@b22-ott-11-8211]   USA       1,084/102,782         1993--1999           Population            ICC; ECC            Case--control      Age, sex, race/ethnicity, cholecochal cysts, cholangitis, biliary cirrhosis, cholelithiasis, cholecystolithiasis, choledocholithiasis, liver flukes, nonspecific cirrhosis, HCV infection, type 2 diabetes mellitus, Crohn's disease, ulcerative colitis, duodenal ulcer, chronic pancreatitis, smoking, obesity   3.1 (1.3--7.5)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              4.5 (2.2--9.1)

  Cai et al, 2011[@b24-ott-11-8211]      China     313/608               2000--2004           Hospital              ECC                 Case--control      Choledocholithiasis, hepatolithiasis, cholecystolithiasis, biliary ascariasis, liver fluke and liver schistosomiasis, HBV infection, HCV infection, PSC, UC, type 2 diabetes mellitus, alcohol, and smoking                                                                                                        1.95 (0.27--13.90)

  Welzel et al, 2011[@b23-ott-11-8211]   USA       743/195,953           1994--2005           Population            ICC                 Case--control      Age, gender, race, geographic location, and Medicare/Medicaid dual enrollment                                                                                                                                                                                                                                      5.69 (3.65--8.86)

  Chang et al, 2013[@b25-ott-11-8211]    Taiwan    5,157/20,148          2004--2008           Population            ICC; ECC            Case--control      Sex, age, cholangitis, cholelithiasis, cholecystitis, cirrhosis of liver, liver flukes, HBV infection, HCV infection, diabetes, chronic pancreatitis, inflammatory bowel disease, and peptic ulcer                                                                                                                 3.8 (2.9--5.0)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              2.5 (1.7--3.6)

  Lee et al, 2015[@b21-ott-11-8211]      Korea     276/552               2007--2013           Hospital              ECC                 Case--control      Cigarette smoking, obesity, choledocholithiasis, cholecystolithiasis, hepatolithiasis, ulcerative colitis, thyroid disease, chronic pancreatitis, pypertension, diabetes mellitus, HBV infection, HCV infection, and liver fluke infestation                                                                       1.08 (0.42--2.78)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ECC, extrahepatic cholangiocarcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; ICC, intrahepatic cholangiocarcinoma; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.

###### 

Scores of the Newcastle-Ottawa scale for the included studies

  Study/year of publication              Fully defined cases   Representative cases   Selection of controls   Definition of controls   Controlling the important factors or confounding factors   Determination of exposure   Same method of determination for cases and controls   Non-response rate   Total score
  -------------------------------------- --------------------- ---------------------- ----------------------- ------------------------ ---------------------------------------------------------- --------------------------- ----------------------------------------------------- ------------------- -------------
  Lee et al, 2015[@b21-ott-11-8211]      ^\*^                  ^\*^                                           ^\*^                     ^\*\*^                                                     ^\*^                        ^\*^                                                  ^\*^                8
  Shaib et al, 2005[@b27-ott-11-8211]    ^\*^                  ^\*^                                           ^\*^                     ^\*^                                                       ^\*^                        ^\*^                                                  ^\*^                7
  Welzel et al, 2007[@b22-ott-11-8211]   ^\*^                  ^\*^                   ^\*^                    ^\*^                     ^\*\*^                                                     ^\*^                        ^\*^                                                                      8
  Welzel et al, 2011[@b23-ott-11-8211]   ^\*^                  ^\*^                   ^\*^                    ^\*^                     ^\*\*^                                                     ^\*^                                                                              ^\*^                8
  Cai et al, 2011[@b24-ott-11-8211]      ^\*^                  ^\*^                   ^\*^                    ^\*^                     ^\*^                                                                                   ^\*^                                                                      6
  Welzel et al, 2007[@b26-ott-11-8211]   ^\*^                  ^\*^                   ^\*^                    ^\*^                     ^\*\*^                                                     ^\*^                                                                              ^\*^                8
  Chang et al, 2013[@b25-ott-11-8211]    ^\*^                  ^\*^                                           ^\*^                                                                                                            ^\*^                                                  ^\*^                5

**Note:** The asterisks represent a score (number of stars).

###### 

Subgroup and sensitivity analyses of the effect of alcoholic liver disease and the risk of cholangiocarcinoma

  Subgroup                                       No. of studies   OR (95% CI)         I[@b2-ott-11-8211] value (%)   *P*-value
  ---------------------------------------------- ---------------- ------------------- ------------------------------ -----------
                                                                                                                     
  All studies                                    7                3.52 (1.96--5.07)   70.2                           0.003
  Subtype of cancer                                                                                                  
   ECC                                           4                2.12 (0.90--3.35)   44.5                           0.145
   ICC                                           5                4.49 (3.06--5.92)   29.2                           0.240
                                                                                                                     
  Geographic areas                                                                                                   
   West                                          4                5.15 (3.34--6.96)   14.6                           0.319
   East                                          3                2.14 (0.38--3.91)   75.7                           0.016
                                                                                                                     
  **Adjustment for confounders**                                                                                     
                                                                                                                     
  Gallstones                                                                                                         
   Yes                                           5                2.52 (1.09--3.96)   61.2                           0.035
   No                                            2                6.13 (3.97--8.30)   0                              0.497
                                                                                                                     
  Hepatitis B/C                                                                                                      
   Yes                                           4                2.48 (1.06--3.91)   67.3                           0.027
   No                                            3                6.20 (4.04--8.36)   0                              0.559
                                                                                                                     
  Cholangitis                                                                                                        
   Yes                                           3                3.14 (2.47--3.82)   0                              0.603
   No                                            4                4.19 (0.70--7.68)   77.5                           0.001
                                                                                                                     
  **Sensitivity analyses**                                                                                           
                                                                                                                     
  Fixed-effects vs random-effects model method                                                                       
   Fixed-effects model                           7                2.87 (2.31--3.44)   70.2                           0.003
   Random-effects model                          7                3.52 (1.96--5.07)   70.2                           0.003

**Note:** *P*-value is for heterogeneity.

**Abbreviations:** ECC, extrahepatic cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.
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